Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.
Rosiñol L, Montoto S, Cibeira MT, Bladé J. Bortezomib-Induced Severe Hepatitis in Multiple MyelomaA Case Report. Arch Intern Med. 2005;165(4):464–465. doi:10.1001/archinte.165.4.464
Customize your JAMA Network experience by selecting one or more topics from the list below.